SIGA NASDAQ
SIGA Technologies, Inc.
1W: -6.7%
1M: -14.8%
3M: -26.8%
YTD: -46.7%
1Y: -53.2%
3Y: -21.0%
5Y: -24.8%
$3.34
+0.24 (+7.74%)
Weekly Expected Move ±7.9%
$3
$3
$3
$3
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$239.6M
52W Range3.01-9.62
Volume1,172,295
Avg Volume613,703
Beta0.89
Dividend$1.20
Analyst Ratings
Company Info
CEODiem Nguyen
Employees49
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date1997-09-10
Websitesiga.com
31 East 62nd Street
New York City, NY 10065
US
New York City, NY 10065
US
212 672 9100
About SIGA Technologies, Inc.
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.
Latest News
Connecticut's first case of clade I mpox + ANDV virus
SIGA expects Q2 delivery of approximately $13M of oral TPOXX while targeting an FDA PEP submission in the next 12 months
SIGA Technologies, Inc. Q1 2026 Earnings Call Summary
SIGA (SIGA) Q1 2026 Earnings Call Transcript
SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Nabel Gary J. | M-Exempt | 24,116 | — | 2026-06-09 |
| Nabel Gary J. | D-Return | 7,235 | $4.39 | 2026-06-09 |
| Nabel Gary J. | M-Exempt | 24,116 | — | 2026-06-09 |
| Nabel Gary J. | A-Award | 34,169 | — | 2026-06-09 |
| KEANE JOHN M | M-Exempt | 24,116 | — | 2026-06-09 |